Home Newsfeeds UBS Maintains Neutral on Carter’s, Lowers Price Target to $72

UBS Maintains Neutral on Carter’s, Lowers Price Target to $72

UBS analyst Jay Sole maintains Carter's (NYSE:CRI) with a Neutral and lowers the price target from $100 to $72.

byBenzinga Newsdesk

July 15, 2022

1 minute read

UBS analyst Jay Sole maintains Carter’s (NYSE:CRI) with a Neutral and lowers the price target from $100 to $72.

What’s Going On With Microvision (MVIS) Shares

By Henry Khederian

June 6, 11:00 AM

Microvision Inc (NASDAQ: MVIS) shares are trading higher by 20.6% to $6.43 Tuesday, despite a lack of company-specific news.

MVIS

Ross Gerber Lauds Tesla’s Clean Energy Solution: ‘Gas Is Stupid At This Point’

By Benzinga Neuro

September 6, 4:20 AM

Gerber Kawasaki CEO Ross Gerber has once again championed Tesla Inc. (NASDAQ:TSLA) as the superior clean energy solution. Gerber took to X,…

TSLA

Humanigen’s Lenzilumab Being Studied As A Potential First Treatment In Thirty Years With A Novel Mechanism Of Action For Chronic Myelomonocytic Leukemia (CMML), An Orphan Form Of Leukemia

By Happy Mohamed

April 14, 12:07 PM

CMML is an aggressive, poorly understood cancer; approximately 20% of patients survive three years from diagnosis Eleven subjects dosed with lenzilumab and with current standard of care, azacitidine

HGEN

GM, Ford Shares Near New 52-Week Lows: Why UBS Is Concerned About Legacy Automakers

By Dylan Wechsler

July 6, 1:57 PM

As consumer spending and pricing power decrease, the automotive industry continues to struggle.

UBS Maintains Neutral on Carter’s, Lowers Price Target to $72

Related Posts

What’s Going On With Microvision (MVIS) Shares

Ross Gerber Lauds Tesla’s Clean Energy Solution: ‘Gas Is Stupid At This Point’

Humanigen’s Lenzilumab Being Studied As A Potential First Treatment In Thirty Years With A Novel Mechanism Of Action For Chronic Myelomonocytic Leukemia (CMML), An Orphan Form Of Leukemia

GM, Ford Shares Near New 52-Week Lows: Why UBS Is Concerned About Legacy Automakers